Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 167

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Open access
Di Blasi, Roberta, Le Gouill, Steven, Bachy, Emmanuel, Cartron, Guillaume, Beauvais, David, Le Bras, Fabien, Gros, François-Xavier, Choquet, Sylvain, Bories, Pierre, Feugier, Pierre, Casasnovas, Olivier, Bay, Jacques Olivier, Mohty, Mohamad, Joris, Magalie, Gastinne, Thomas, Sesques, Pierre, Tudesq, Jean-Jacques, Vercellino, Laetitia, Morschhauser, Franck, Gat, Elodie, Broussais, Florence, Houot, Roch, Thieblemont, Catherine · 2022 · Blood

Abstract

Anti-CD19 chimeric antigen receptor (CAR) T-cells represent a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas. However, a significant number of patients experience failure. Among 550 patients registered in the French registry DESCAR-T, 238 (43.3%) experienced progression/relapse, with a median follow-up of 7.9 months. At registration, 57.0% of patients presented an age-adjusted International Prognostic Index of 2 to 3, 18.9% had Eastern Cooperative Oncology Group performance status ≥2, 57.1% received >3 lines of treatment prior to receiving CAR T-cells, and 87.8% received bridging therapy. At infusion, 66% of patients presented progressive disease, and 38.9% had high lactate dehydrogenase (LDH). Failure after CAR T-cell treatment occurred after a median of 2.7 months (range: 0.2-21.5). Fifty-four patients (22.7%) presented very early failure (day [D] 0-D30); 102 (42.9%) had early failure (D31-D90), and 82 (34.5%) had late (>D90) failure. After failure, 154 patients (64%) received salvage treatment: 38.3% received lenalidomide, 7.1% bispecific antibodies, 21.4% targeted treatment, 11% radiotherapy, and 20% immunochemotherapy with various regimens. Median progression-free survival was 2.8 months, and median overall survival (OS) was 5.2 months. Median OS for patients failing during D0-D30 vs after D30 was 1.7 vs 3.0 months, respectively (P = .0001). Overall, 47.9% of patients were alive at 6 months, but only 18.9% were alive after very early failure. In multivariate analysis, predictors of OS were high LDH at infusion, time to CAR-T failure <D30, and high C-reactive protein at infusion. This multicentric analysis confirms the poor outcome of patients relapsing after CAR T-cell treatment, highlighting the need for further strategies dedicated to this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2022016945

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 167

Metadata

Authors
Di Blasi, R., Le Gouill, S., Bachy, E., Cartron, G., Beauvais, D., Le Bras, F., Gros, F.-X., Choquet, S., Bories, P., Feugier, P., Casasnovas, O., Bay, J. O., Mohty, M., Joris, M., Gastinne, T., Sesques, P., Tudesq, J.-J., Vercellino, L., Morschhauser, F., Gat, E., Broussais, F., Houot, R., & Thieblemont, C.
Venue
Blood
Published
2022-12-15
Volume
140
Issue
24
Pages
2584-2593
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4296301794
Cited by
167
References
4
FWCI
11.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. https://app.cochat.ai/papers/10.1182/blood.2022016945
The paper
Di Blasi, R., Le Gouill, S., Bachy, E., Cartron, G., Beauvais, D., Le Bras, F., Gros, F.-X., Choquet, S., Bories, P., Feugier, P., Casasnovas, O., Bay, J. O., Mohty, M., Joris, M., Gastinne, T., Sesques, P., Tudesq, J.-J., Vercellino, L., Morschhauser, F., . . . Thieblemont, C. (2022). Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. https://doi.org/10.1182/blood.2022016945

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.